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In February 2008, the ERA-EDTA launched NDT Plus under
the editorship of Norbert Lameire with the aim of provid-
ing an educational and training resource focusing on post-
graduate clinical education and topics of interest to the
practising nephrologist [1]. Four years later, NDT Plus
evolved into the Clinical Kidney Journal (CKJ) [2]. February
2012 saw the birth of CKJ, a name change that was part of
a more profound evolution in editorial policy [3]. The new
policy aimed at keeping the journal educational yet
making it more academic and providing more and better
content [2]. Under the leadership of Alain Meyrier, the
journal ﬂourished and accomplished its mission [4]. The
emphasis on quality resulted in a 60% rejection rate. As a
result, nephrologists, kidney pathologists and kidney re-
searchers were provided with an impressive array of high-
quality manuscripts covering clinical nephrology, kidney
pathology, dialysis and transplantation. In his farewell edi-
torial comment, Alain himself picked a beautiful collection
of his favourite in-depth reviews ranging from recent ad-
vances in Balkan endemic nephropathy [5] to novel cellu-
lar and molecular aspects of vasopressin [6] or more
practical approaches to the evaluation of kidney injury by
anticancer drugs [7] or the prescription of anticoagulation
in chronic kidney disease [8].
The next chapter in the history of CKJ starts with this
February 2015 issue of the journal and will further empha-
size quality since we believe that the best way to contrib-
ute to education that positively impacts patient outcomes
is to provide high-quality content authored by top-level
clinical and translational researchers and clinicians. We
propose to maintain the educational and clinically orien-
tated focus while gradually expanding the clinical applica-
tions of translational research. Translation into clinical
practice is the ultimate goal of research, and clinical prac-
tice should have an impact on research aims and scope.
We aim to contribute to a translational research culture
among nephrologists that helps close the gap between
basic researchers and practising clinicians and promote
sorely needed innovations in the ﬁeld of nephrology [9]. In
this regard, chronic kidney disease is among the top three
fastest growing main causes of death worldwide [10], and
despite general advances in patient care, the mortality of
chronic kidney failure patients remains far higher than in
the age-matched general population [11]. To reﬂect this
widened scope, a sub-heading has been added to the
journal name, emphasizing the new focus: Clinical and
Translational Nephrology. The scopewill be further expanded
to include educational research in nephrology while kidney
pathology will also remain a focus of the journal. A series of
changes will help implement this new agenda.
Open access
Starting January 2015, the journal will become fully open
access and online-only. This will allow access to its entire
content across the globe to trainees and established ne-
phrologists, pathologists and researchers alike.
Expanded scope
Nephrology has lagged behind other specialties in clinical
translation of basic research advances, and there is also a
considerable lag time between clinical advances and their
widespread implementation into daily clinical practice.
Thus, as an educational and academic journal committed
to improving patient outcomes, CKJ is moving from a limited
focus on clinical practice to a wider view that promotes the
values of translational medicine among nephrologists and
kidney pathologists. Translational research, clinical practice
and educational issues and research are three key contribu-
tors to the successful translation of translational research
advances into clinical advances and the successful imple-
mentation of clinical advances into routine patient care.
In this regard, successful implementation greatly depends
on using the most appropriate educational strategies
to target healthcare personnel, patients and healthcare
decision-makers.
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Streamlining the types of manuscripts
CKJ will publish three main types of manuscripts: editorial
comments, CKJ reviews and original articles.
Editorial comments will remain by invitation only and
will refer to recent CKJ original articles or to recent ad-
vances or controversies in nephrology.
CKJ reviews will deal with clinical nephrology, dialysis,
transplantation, kidney pathology and nephrological
educational research. These will usually be by invitation
but suggestions for titles are welcomed. We recognize
the educational aspects of case reports and the focus
they put on patient outcomes. Thus, we encourage the
inclusion within the review of a vignette containing a
case report that illustrates concepts discussed in the
review. In this regard, a section should be added sum-
marizing the key messages of the review including one
item on how this knowledge may impact patient out-
comes and what barriers should be overcome. A series of
reviews has already been planned that will explore CKD
hotspots around the world [12–14], translational re-
search in nephrology [15], education and education re-
search in nephrology and molecular pathology. In this
section we will also publish reviews produced by the
ERA-EDTA Scientiﬁc Working Groups, including the Euro-
pean Renal and Cardiovascular medicine (EURECA-m)
working group (WG), the Immunonephrology WG, the
WG on Inherited Kidney Disorders (WGIKD), the Euro-
pean Dialysis WG (EUDIAL), Developing Education
Science and Care for Renal Transplantation in European
States (DESCARTES), Working Group on Chronic Kidney
Disease–Mineral and Bone Disorders (CKD-MBD) and the
working group researching the nephrological impact in
relation to diabetes and obesity (DIABESITY) [16]. One
section will also be devoted to clinical practice guidelines
or position statements.
Original manuscripts may deal with clinical or trans-
lational issues in nephrology, dialysis, transplantation,
hypertension, electrolytes, kidney pathology or education-
al research. Clinical trials, including design, baseline or
negative ones, will also be considered for publication.
Exceptional case reports that may impact the practice of
nephrology or advanced key pathophysiological concepts
will be considered for publication on a very selective basis.
Letters to the editor related to the contents of the
journal will also be considered.
Editorial board
The editorial board will gradually change to ﬁt the new
scope of the journal. CKJ has been extremely well served
by a great number of superb Editorial Board members. We
are most grateful to the Editorial Board team and dedi-
cated reviewers that have made CKJ the high-quality
journal that it is today. In addition, we welcome the new
members who are leaders in their ﬁelds and expand the
knowledge base to face the challenges ahead. Carmine
Zoccali will act as Associate Editor. Kenar Jhaveri will deal
with educational research and Helen Liapis will contribute
her profound knowledge of molecular pathology, Andreas
Linkermann his experience with basic research and Ionut
Nistor and Sabine van der Veer their methodological back-
ground acquired in the European Renal Best Practice
(ERBP) working group.
Editorial assistance
Some aspects of CKJ will not change. Thus, the excellent
editorial assistance will continue to be provided by
Caroline Vinck and Claudia Brügmann.
We expect that the new focus and format of CKJ, along
with the high-quality and hard work of the authors, re-
viewers, editorial board members and editorial assistants,
will result in an enjoyable, thought-provoking read that
will not only educate about speciﬁc aspects of diseases or
patient care but will also promote the values and culture
of translational science among nephrologists and related
specialists, with the ultimate aim of improving kidney
patient care and outcomes.
In 3 years time, we hope to deliver to the next Editor-in-
Chief a highly respected journal with a faithful readership
and a matching impact factor.
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